ArticleScientific reports2016
Presence of retinal pericyte-reactive autoantibodies in diabetic retinopathy patients.
Article in Scientific reports, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 31 citations in OpenAlex.
- Transcriptomic Characterization of Terminal Complement Complex-bound Cells in Human Choroid Using Single-Cell RNA Sequencing.bioRxiv : the preprint server for biology · 2026Article
- C3a and C5a plasma concentrations in patients with diabetic retinopathy: a cross-sectional study.International journal of retina and vitreous · 2026Article
- Shared signaling pathways and comprehensive therapeutic approaches among diabetes complications.Frontiers in medicine · 2024Review
- Protective effects of nattokinase against microvasculopathy and neuroinflammation in diabetic retinopathy.Journal of diabetes · 2023Article
- Circulating Biomarkers to Predict Diabetic Retinopathy in Patients with Diabetic Kidney Disease.Vision (Basel, Switzerland) · 2023Review
- Anomalies in neurovascular coupling during early diabetes: A review.Clinical & experimental ophthalmology · 2023Review
- The innate immune system in diabetic retinopathy.Progress in retinal and eye research · 2021Review
- Pericytes, inflammation, and diabetic retinopathy.Inflammopharmacology · 2020Review
- Pericytes enable effective angiogenesis in the presence of proinflammatory signals.Proceedings of the National Academy of Sciences of the United States of America · 2019Article
- Modulation of three key innate immune pathways for the most common retinal degenerative diseases.EMBO molecular medicine · 2018Review
- Therapeutic potential of staphylococcal superantigen-like protein 7 for complement-mediated hemolysis.Journal of molecular medicine (Berlin, Germany) · 2018Article
- Plasma Exosomes Contribute to Microvascular Damage in Diabetic Retinopathy by Activating the Classical Complement Pathway.Diabetes · 2018Article
- Obesity-induced metabolic disturbance drives oxidative stress and complement activation in the retinal environment.Molecular vision · 2018Article
- New insight into the role of the complement in the most common types of retinopathy-current literature review.International journal of ophthalmology · 2018Review
- Metformin inhibits development of diabetic retinopathy through microRNA-497a-5p.American journal of translational research · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 6 institutions in 2 countries.
Funding
Abstract
The loss of retinal pericytes (RPCs) is a hallmark of early stage diabetic retinopathy (DR), but the mechanism underlying RPC death is unclear. Although it was postulated in previous studies using bovine RPCs that autoantibodies against RPCs might develop and induce RPC death, it is unknown whether autoantibodies against cell-surface antigens on human RPCs exist in DR patients, whether such autoantibodies contribute to RPC damage/loss, and if they do, through which mechanism. We screened serum samples from DR patients and controls using primary human RPCs and found that that levels of IgGs reactive to RPCs were significantly higher in the DR group than the control group. Serum samples with higher RPC-reactive IgG levels induced more severe complement-mediated RPC damage than those with lower RPC-reactive IgG levels. We also assessed levels of the complement-activation products C3a, C4a and C5a in these serum samples, and found that serum levels of C3a and C5a, but not C4a, were higher in the DR group than control group. These data provide evidence the first time showing that autoantibodies against RPCs can develop in DR patients, and that these autoantibodies could contribute to pericyte damage through complement activation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.